Expansion of the clinical spectrum associated with AARS2-related disorders.
Siddharth SrivastavaAnkur ButalaSonal MahidaJohn RichterWeiyi MuAndrea PorettiHilary VernonJay VanGerpenPaldeep S AtwalErik H MiddlebrooksDavid S ZeeSakkuBai NaiduPublished in: American journal of medical genetics. Part A (2019)
Biallelic pathogenic variants in AARS2, a gene encoding the mitochondrial alanyl-tRNA synthetase, result in a spectrum of findings ranging from infantile cardiomyopathy to adult-onset progressive leukoencephalopathy. In this article, we present three unrelated individuals with novel compound heterozygous pathogenic AARS2 variants underlying diverse clinical presentations. Patient 1 is a 51-year-old man with adult-onset progressive cognitive, psychiatric, and motor decline and leukodystrophy. Patient 2 is a 34-year-old man with childhood-onset progressive tremor followed by the development of polyneuropathy, ataxia, and mild cognitive and psychiatric decline without leukodystrophy on imaging. Patient 3 is a 57-year-old woman with childhood-onset tremor and nystagmus which preceded dystonia, chorea, ataxia, depression, and cognitive decline marked by cerebellar atrophy and white matter disease. These cases expand the clinical heterogeneity of AARS2-related disorders, given that the first and third case represent some of the oldest known survivors of this disease, the second is adult-onset AARS2-related neurological decline without leukodystrophy, and the third is biallelic AARS2-related disorder involving a partial gene deletion.
Keyphrases
- cognitive decline
- multiple sclerosis
- copy number
- early onset
- deep brain stimulation
- case report
- white matter
- mild cognitive impairment
- parkinson disease
- heart failure
- oxidative stress
- genome wide
- depressive symptoms
- young adults
- dna methylation
- high resolution
- photodynamic therapy
- genome wide identification
- blood brain barrier
- brain injury
- autism spectrum disorder